Table 1 Characteristics of patient and donor (graft) and clinical outcomes between the two groups

Median age, yr (range)

29 (6–56)

34.5 (4–69)

0.024

Age, no. (%)

< 0.001

 < 20 yr

17 (15.7)

24 (23.1)

 20–40 yr

67 (62.0)

32 (30.8)

 ≥ 40 yr

24 (22.2)

48 (46.2)

Sex, no. (%)

0.767

 Male

57 (52.8)

57 (54.8)

 Female

51 (47.2)

47 (45.2)

Disease status, no. (%)

0.831

 SAA

68 (66.7)

64 (61.5)

 vSAA

40 (33.3)

40 (38.5)

With PNH clone, no. (%)

26 (24.1)

19 (10.2)

0.301

ECOG score, median (range)

1 (0–2)

1 (0–2)

0.537

Median time from diagnosis to treatment, mth (range)

3 (1.0–200)

2 (0.5–240)

0.011

Median time to an ANC ≥ 1.0 × 10⁹/L, d (range)

15 (11–35)

30 (4–58)

0.002

Median time to transfusion independence for RBCs, d (range)

22 (13–32)

63 (6–302)

< 0.001

Median time to transfusion independence for platelets, d (range)

12 (8–52)

52 (11–287)

< 0.001

Normal blood routine at 6-mth, no. (%)

83 (86.5)

23 (23.7)

< 0.001

Early death, no (%)

7 (6.5)

2 (1.9)

0.192

Secondary clonal disease, no (%)

1 (0.9)

2 (2.9)

0.587

Relapsed, no (%)

0 (0.0)

1 (0.9)

–

Alternative donor transplantation, no (%)

0 (0.0)

10 (9.6)

–

TRM, no (%)

17 (15.7)

10 (9.6)

0.181

 Secondary GF, no (% of TRM)

1 (5.9)

–

 aGVHD, no (% of TRM)

1 (5.9)

–

 cGVHD, no (% of TRM)

1 (5.9)

–

 TMA, no (% of TRM)

2 (11.8)

–

 Poor graft function, no (% of TRM)

1 (5.9)

–

 Infection, no (% of TRM)

9 (52.8)

5 (50.0)

 Intracranial hemorrhage, no (% of TRM)

1 (5.9)

2 (20.0)

 Heart failure, no (% of TRM)

–

1 (10.0)

 Other, no (% of TRM)

1 (5.9)

2 (20.0)

Median follow-up time among living patients, mth (range)

31.5 (13.0–69.0)

30.5 (14.0–66.0)

0.589

Conditioning regimen

Flu + CY + ATG

rATG (pALG) + CsA + EPAG

Donor median age, yr (range)

30 (10–55)

–

Donor sex, no. (%)

–

 Male

54 (50.0)

–

 Female

54 (50.0)

–

Blood types of donor to recipient, no. (%)

 Matched

65 (60.2)

–

 Major mismatched

15 (13.9)

–

 Minor mismatched

19 (17.6)

–

 Major and minor mismatched

9 (8.3)

–

Source of graft, no. (%)

 BM

4 (3.7)

–

 PB

30 (27.8)

–

 BM + PB

74 (68.5)

–

Median MNC, × 10⁸/kg (range)

11.6 (3.2–24.4)

–

Median CD34⁺ cells, × 10⁶/kg (range)

3.7 (1.1–8.6)

–

Median time to ANC > 0.5 × 10⁹/L, d (range)

11 (7–21)

–

Median time to PLT > 20.0 × 10⁹/L, d (range)

12 (8–52)

–

Primary GF, no. (%)

0 (0.0)

–

Secondary GF, no. (%)

2 (1.9)

–

GF of platelet, no. (%)

3 (2.9)

–

Delayed platelet recovery, no. (%)

4 (3.8)

–

Poor graft function, no. (%)

1 (0.9)

–

Adverse events of attributed to EPAG, no. (%)

 Skin (maculopapular and/or rash pruritus)

–

3 (2.9)

 Abdominal pain

–

2 (1.9)

 Joint pain

–

2 (1.9)

 Liver test abnormality

  Increased aminotransferase level

–

42 (40.4)

  Increased blood bilirubin level

–

19 (18.3)